Researchers from the University of Miami’s Miller School of Medicine are developing a new treatment for myasthenia gravis, a chronic autoimmune disorder that affects the neuromuscular space. The disease is caused by the immune system attacking the receptors that transmit signals between nerves and muscles, leading to muscle weakness and fatigue.

The team has developed a therapeutic vaccine that targets the immune system’s T-cells, which play a role in the disease. The vaccine uses a small protein fragment called a peptide, which is designed to train the T-cells to recognize and tolerate the receptors.

In early trials, the vaccine was shown to be safe and well-tolerated, with no significant adverse effects reported. The team is now planning to move into larger clinical trials to evaluate the vaccine’s effectiveness in treating myasthenia gravis.

If successful, the vaccine could provide a new treatment option for patients with myasthenia gravis, who currently rely on drugs that suppress the immune system or improve nerve-muscle transmission.

Read more: https://www.appliedclinicaltrialsonline.com/view/examining-the-neurology-neuromuscular-space